The Hill
BY MAUREEN BRESLIN – 10/27/21 09:09 PM EDT
An affordable antidepressant has been found in a clinical trial to reduce the risk of hospitalization in high-risk adults with recently diagnosed COVID-19, according to a study published in The Lancet Global Health.
The drug, known as fluvoxamine, is a selective serotonin reuptake inhibitor (SSRI) commonly used in the treatment of depression, anxiety, obsessive-compulsive disorder and other mood disorders. Its low price makes it a desirable treatment option for less wealthy nations, the researchers wrote.
Super Sleuth
